Table 3: Data dictionary for apollo_drugChoiceData.csv

 $\begin{array}{c|c} \text{Individuals} & 1,000 \\ \text{Observations} & 10,000 \end{array}$

Variable	Description	Values
ID	Unique respondent ID	1 to 1,000
task	Index for SP choice tasks	1 to 10
best	first ranked alternative	1 to 4
second pref	second ranked alternative	1 to 4
$\operatorname{third} \operatorname{pref}$	third ranked alternative	1 to 4
worst	worst ranked alternative	1 to 4
$\frac{1}{\text{brand}}$	brand for first alternative	Artemis; Novum
$\operatorname{country}_{1}$	country for first alternative	Switzerland; Denmark; USA
${ m char}_1$	characteristics for first alternative	standard; fast acting; double strength
$side_effects_1$	risk of side effects for first alternative	Min: 1/100,000, mean: 37/100,000, max: 100/100,000
price 1	price (\mathcal{L}) for first alternative	Min: 2.25, mean: 3.15, max: 4.5
$\frac{1}{b}$ brand $\frac{1}{2}$	brand for second alternative	Artemis; Novum
country 2	country for second alternative	Switzerland; Denmark; USA
$\operatorname{char} _{-2}^{-2}$	characteristics for second alternative	standard; fast acting; double strength
${\rm side_effects_2}$	risk of side effects for second alternative	Min: 1/100,000, mean: 37/100,000, max: 100/100,000
pries 2	price (\mathcal{L}) for second alternative	Min: 2.25, mean: 3.15, max: 4.5
$\frac{\text{price}}{\text{brand}}\frac{2}{3}$	brand for third alternative	BestValue; Supermarket; PainAway
country 3	country for third alternative	USA; India; Russia; Brazil
char 3	characteristics for third alternative	standard; fast acting
side effects 3	risk of side effects for third alternative	Min: 10/100,000, mean: 370/100,000,
side_enects_5	risk of side effects for third afternative	max: 1,000/100,000 mean: 370/100,000,
price_3	price (\mathcal{L}) for third alternative	Min: 0.75, mean: 1.75, max: 2.5
$\frac{1}{\text{brand}}$	brand for fourth alternative	BestValue; Supermarket; PainAway
$\operatorname{country}_{-4}$	country for fourth alternative	USA; India; Russia; Brazil
char_{-4}	characteristics for fourth alternative	standard; fast acting
${\rm side_effects_4}$	risk of side effects for fourth alternative	Min: 10/100,000, mean: 370/100,000, max: 1,000/100,000
price 4	price (\mathcal{L}) for fourth alternative	Min: 0.75, mean: 1.75, max: 2.5
regular user	dummy variable for regular users	1 for regular users, 0 otherwise
university_educated	dummy variable for university educated	1 for university educated, 0 otherwise
over 50	dummy variable for age over 50 years	1 for age over 50 years, 0 otherwise
attitude quality	Answer to "I am concerned about the	Likert scale from 1 (strongly disagree)
_ 1	quality of drugs developed by unknown companies"	to 5 (strongly agree)
attitude_ingredients	Answer to "I believe that ingredients are	Likert scale from 1 (strongly disagree)
8	the same no matter what the brand"	to 5 (strongly agree)
attitude patent	Answer to "The original patent hold-	Likert scale from 1 (strongly disagree)
	ers have valuable experience with their medecines"	to 5 (strongly agree)
$attitude_dominance$	Answer to "I believe the dominance of	Likert scale from 1 (strongly disagree)
	big pharmaceutical companies is un- helpful"	to 5 (strongly agree)